Overview
AN2 Therapeutics reports Q3 net loss of $9.4 mln, improved from $12.7 mln last year
Company's R&D expenses decreased to $7 mln from $8.3 mln in Q3 2024
AN2 advances Phase 1 trial for Chagas disease, collaborates with GSK on TB research
Outlook
AN2 expects to initiate Phase 2 Chagas disease study in 2026
Company plans to advance first oncology compound in early 2026
AN2 projects cash reserves to sustain operations into 2028
Result Drivers
R&D EXPENSES - Decline due to decreased clinical trial expenses, personnel-related expenses, chemistry manufacturing and controls expenses, and consulting and outside services
RESTRUCTURING CHARGES - No restructuring charges compared to $2.2 mln a year ago due to severance payments and other employee termination-related expenses
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 EPS | -$0.31 | ||
Q3 Net Income | -$9.35 mln | ||
Q3 Income From Operations | -$10.04 mln | ||
Q3 Operating Expenses | $10.04 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for AN2 Therapeutics Inc is $1.50, about 20% above its November 11 closing price of $1.20
Press Release: ID:nBw6YppsFa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)